Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaBRA: Carboplatin in BRCA-Mutated or Neuroendocrine-Differentiated mHSPC
NCT07591467Phase 3Not yet recruiting
- Sponsor
- Gustave Roussy
- Start
- Sep 2026
- Primary completion
- Sep 2036
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised trial of carboplatin in prostate cancer (PCa) (2 arms), sponsored by Gustave Roussy. Primary endpoint: Radiographic progression-free survival up to 10 years. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
carboplatin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07591467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07591467.